TESARO, Inc. (TSRO) Given a $151.00 Price Target at Credit Suisse Group
Credit Suisse Group set a $151.00 target price on TESARO, Inc. (NASDAQ:TSRO) in a research note released on Thursday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts have also recently issued reports on the stock. Morgan Stanley began coverage on shares of TESARO in a report on Friday. They set an overweight rating for the company. Leerink Swann reiterated an outperform rating and set a $152.00 price objective (up from $115.00) on shares of TESARO in a report on Monday. FBR & Co lifted their price objective on shares of TESARO from $133.00 to $151.00 and gave the company an outperform rating in a report on Tuesday, December 27th. Robert W. Baird reiterated an outperform rating and set a $127.00 price objective on shares of TESARO in a report on Thursday, December 22nd. Finally, Wedbush reiterated an outperform rating and set a $139.00 price objective on shares of TESARO in a report on Wednesday, December 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $120.47.
TESARO (NASDAQ:TSRO) traded up 6.460% on Thursday, reaching $156.475. 813,111 shares of the company’s stock traded hands. The stock’s market cap is $8.08 billion. The company’s 50 day moving average is $134.61 and its 200-day moving average is $107.12. TESARO has a 52-week low of $29.51 and a 52-week high of $157.77.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.98) EPS for the quarter, missing analysts’ consensus estimates of ($1.92) by $0.06. The company earned $3.73 million during the quarter, compared to analyst estimates of $4.39 million. TESARO had a negative return on equity of 141.88% and a negative net margin of 798.68%. The company’s revenue for the quarter was up 4187.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.66) earnings per share. Equities analysts expect that TESARO will post ($7.41) EPS for the current year.
In other news, SVP Martin H. Jr. Huber sold 190 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $136.26, for a total value of $25,889.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Martin H. Jr. Huber sold 327 shares of the business’s stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $121.29, for a total transaction of $39,661.83. Following the completion of the sale, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $223,416.18. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its stake in TESARO by 16.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 5,584,279 shares of the biopharmaceutical company’s stock valued at $559,768,000 after buying an additional 776,709 shares during the period. Passport Capital LLC acquired a new stake in TESARO during the second quarter valued at about $61,720,000. FMR LLC raised its stake in TESARO by 9.6% in the second quarter. FMR LLC now owns 6,097,449 shares of the biopharmaceutical company’s stock valued at $512,490,000 after buying an additional 531,892 shares during the period. Pictet Asset Management Ltd. raised its stake in TESARO by 661.3% in the second quarter. Pictet Asset Management Ltd. now owns 418,730 shares of the biopharmaceutical company’s stock valued at $19,387,000 after buying an additional 363,730 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in TESARO by 249.0% in the third quarter. Bank of New York Mellon Corp now owns 493,701 shares of the biopharmaceutical company’s stock valued at $49,490,000 after buying an additional 352,228 shares during the period. 97.40% of the stock is currently owned by institutional investors.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.